Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
NCT ID: NCT03770468
Last Updated: 2024-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
599 participants
OBSERVATIONAL
2015-07-05
2023-08-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1)
* Identification of molecular tumor characteristics in long-term survivors (Focus 2)
* Assessment of therapy-related parameters, including neuro-toxicity (Focus 3)
* Immunological studies (Focus 4)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Disease Progression and Treatment-induced Alterations in Glioblastoma
NCT02152748
Clinical and Treatment Determinant of Prognosis in Glioblastoma
NCT07197086
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
NCT02458508
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
NCT04219475
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood drawl
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histopathological diagnosis of glioblastoma (reference histology available) and
* Survival \>5 years from diagnosis
* Availability of tumor tissue from initial glioblastoma diagnosis (FFPE or fresh-frozen) to validate the diagnosis centrally.
* Signed consent form (living patients) or ethics approval for anonymous data collection in case of retrospective analysis of deceased patients
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Weller
Role: PRINCIPAL_INVESTIGATOR
EORTC Study Coordinator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana-Farber Cancer Institute & Harvard Medical School
Boston, Massachusetts, United States
Universitaetsklinikum Wien - AKH uniklinieken
Vienna, , Austria
Hopitaux Universitaires Bordet-Erasme
Brussels, , Belgium
CHU Lyon - Hopital neurologique Pierre Wertheimer
Bron, , France
CHRU de Lille
Lille, , France
Hopitaux de Marseille - Hôpital de La Timone (APHM)
Marseille, , France
Institut du Cancer de Montpellier
Montpellier, , France
CHU de Nice - Hopital Pasteur
Nice, , France
Hopitaux de Paris - Hopital Saint-Louis
Paris, , France
Hopitaux de Paris - La Pitie Salpetriere
Paris, , France
CHU d'Amiens - CHU Amiens - Hopital Sud
Salouël, , France
Universitaetsklinikum Bonn
Bonn, , Germany
Universitaetsklinikum Carl Gustav Carus
Dresden, , Germany
Universitaetsklinikum - Essen
Essen, , Germany
Ronellenfitsch Michael
Frankfurt, , Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, , Germany
UniversitaetsKlinikum Heidelberg
Heidelberg, , Germany
Ludwig-Maximilians-Universitaet Muenchen - Campus Grosshadern
München, , Germany
Technische Universitaet Muenchen - Klinikum Rechts Der Isar
München, , Germany
Universitaetsklinikum Regensburg
Regensburg, , Germany
Hygeia Hospital
Athens, , Greece
Azienda Ospedaliera Di Padova - Istituto Oncologico Veneto IRCCS
Padua, , Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Giovanni
Torino, , Italy
Amsterdam UMC - locatie VUmc
Amsterdam, , Netherlands
Erasmus MC
Rotterdam, , Netherlands
Centre Hospitalier Universitaire Vaudois - Lausanne
Lausanne, , Switzerland
Univ. Spital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EORTC-1419-BTG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.